Infliximab and Adalimumab monoclonal antibodies (mAbs) are used widely to treat rheumatoid arthritis, psoriatic arthritis, and many autoimmune diseases by binding to tumor necrosis factor-alpha (TNFα) to reduce the inflammatory response.
Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.
Infliximab, a chimeric monoclonal antibody, is used to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and other autoimmune diseases.